Zanubrutinib Patent Expiration
Zanubrutinib is used for treating adult patients with various types of lymphomas and leukemias who have not responded to prior therapies. It was first introduced by Beigene Usa Inc
Zanubrutinib Patents
Given below is the list of patents protecting Zanubrutinib, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Brukinsa | US11786531 | Methods of treating B-cell proliferative disorder | Jan 19, 2043 | Beigene |
| Brukinsa | US11896596 | Methods of treating B-cell proliferative disorder | Jan 19, 2043 | Beigene |
| Brukinsa | US11911386 | Methods of treating B-cell proliferative disorder | Jan 19, 2043 | Beigene |
| Brukinsa | US11701357 | Treatment of B cell cancers using a combination comprising Btk inhibitors | Jun 24, 2039 | Beigene |
| Brukinsa | US10927117 | Crystalline form of (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof | Aug 15, 2037 | Beigene |
| Brukinsa | US11591340 | Crystalline form of (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra- hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof | Aug 15, 2037 | Beigene |
| Brukinsa | US11851437 | Crystalline form of (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof | Aug 15, 2037 | Beigene |
| Brukinsa | US11884674 | Crystalline form of (S)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra- hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof | Aug 15, 2037 | Beigene |
| Brukinsa | US11970500 | Crystalline form of (s)-7-(1-acryloylpiperidin-4-yl)- 2-(4-phenoxyphenyl)-4,5,6,7-tetra- hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof | Aug 15, 2037 | Beigene |
| Brukinsa | US10570139 | Substituted pyrazolo[1,5-a]pyrimidines as Bruton's tyrosine kinase modulators | Apr 22, 2034 | Beigene |
| Brukinsa | US11142528 | Substituted pyrazolo[1,5-a]pyrimidines as Bruton's tyrosine kinase modulators | Apr 22, 2034 | Beigene |
| Brukinsa | US9447106 | Substituted pyrazolo[1,5-a]pyrimidines as bruton's tyrosine kinase modulators | Apr 22, 2034 | Beigene |
Zanubrutinib's Family Patents
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List